By Benjamin Chiou
Date: Friday 23 May 2025
(Sharecast News) - Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic obstructive pulmonary disease (COPD) following positive results from phase III trials.
Transaction in Own Shares | 23-May-2025 | 17:38 | RNS |
Form 8.3 - Spirent Communications plc | 23-May-2025 | 15:25 | Business Wire |
Form 8.3 - Spirent Communications plc | 23-May-2025 | 15:20 | RNS |
Form 8.3 - SPIRENT COMMUNICATIONS PLC | 23-May-2025 | 15:00 | Business Wire |
Form 8.3 - Spirent Communications PLC | 23-May-2025 | 14:40 | RNS |
Questor:Meggitt | 23-Dec-2014 | Telegraph |
Questor :KCOM | 27-Nov-2014 | Telegraph |
Questor :Ricardo | 31-Oct-2014 | Telegraph |
Questor:CSR | 17-Oct-2014 | Telegraph |
Questor:BAE Systems | 03-Sep-2014 | Telegraph |
Price | 4,756.71 |
Change Today | -17.83 |
% Change | -0.37 % |
23-May-25 Close | 4,756.71 |
You are here: research